GSK scientist pleads guilty to trade secret theft
04-01-2022
GSK claims Amgen v Sanofi decision “threatens” innovation
29-04-2021
MAXSHOT.PL / Shutterstock.com
Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne (GSK) has added its response to the petition to rehear the case yet again.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, Teva Pharmaceuticals, en banc, Federal Circuit, FDA, generics
